Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs

Clinical Pharmacokinetics

Volumn 41, Issue 6, 2002, Pages 431-444

  Danesi, R ^a   Fogli, S ^a   Gennari, A ^b   Conte, P ^b   Del Tacca, M ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN DERIVATIVE; EPIRUBICIN; IDARUBICIN; PIRARUBICIN; SABARUBICIN; VALRUBICIN;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CARDIOTOXICITY; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; HUMAN; LEUKOPENIA; LIVER DISEASE; MUCOSA INFLAMMATION; NAUSEA; NEOPLASM; NEUTROPENIA; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; VOMITING;

EID: 0036310616     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241060-00004     Document Type: Review

References (55)

1. Practical treatment guide for dose individualisation in cancer chemotherapy
2. Making TDM work to optimize cancer chemotherapy: A multidisciplinary team approach
3. A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy
4. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer
5. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer
6. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
7. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated lipsomal doxorubicin in patients with solid tumors: The relation between pharmacokinetic property and toxicity
8. Iododoxorubicin in advanced breast cancer: A phase II evaluation of clinical activity, pharmacology and quality of life
9. Treatment of AL amyloidosis with 4′-iodo-4′-deoxydoxorubicin: An update
10. Phase I clinical and pharmacological study of oral methoxymorpholinyldoxorubicin (PNU 152243)
11. Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities
12. Pharmacokinetic-pharmacodynamic relationships between pirarubicin exposure and hematotoxicity: Clinical application using only one blood sample
13. Valrubicin
14. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder
15. Population pharmacokinetics in phase I drug development: A phase I study of PK1 in patients with solid tumours
16. Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic-pharmacodynamic modeling
17. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy
18. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein
19. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer
20. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer
21. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group
22. What is the effect of adjusting epirubicin doses for body surface area?
23. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
24. A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement
25. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients
26. Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours
27. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-1-leucyldoxorubicin and its metabolites in a phase I clinical trial
28. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
29. Anthracyclines and other intercalating agents
30. Clinical pharmacokinetics of epirubicin: The importance of liver biochemistry tests
31. Doxorubicin pharmacokinetics: The effect of abnormal liver biochemistry tests
32. Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia
33. Doxorubicin cardiotoxicity in children: Reduced incidence of cardiac dysfunction associated with continuous-infusion schedules
34. The bigger the better? Or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer
35. Epirubicin: A review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer
36. Phase II study of high-dose epirubicin in untreated patients with small-cell lung cancer
37. Gemcitabine, epirubicin and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in advanced breast cancer
38. Pharmacokinetics and toxicity of two schedules of high dose epirubicin
39. Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer
40. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
41. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity
42. Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment
43. Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells
44. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin
45. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart
46. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer
47. Pharmacodynamics in cancer therapy
48. Hematopoiesis and hematopoietic growth factors
49. Doxorubicin metabolism and toxicity in human myocardium: Role of cytoplasmic deglycosidation and carbonyl reduction
50. Role of iron in anthracycline cardiotoxicity: New tunes for an old song?
51. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling
52. Pharmacodynamics of chemotherapeutic effects: Dose-time-response relationships for phase-nonspecific agents
53. Analysis of anti-platelet effect of ticlopidine in humans: Modeling based on irreversible inhibition of platelet precursors in bone marrow
54. Population toxicodynamic analysis of pemetrexed disodium (Alimta)
55. Multiple-dose pharmacokinetics of epirubicin at four different dose levels: Studies in patients with metastatic breast cancer